What is the difference between Hexarelin and MK-677 (Ibutamoren)?

Hexarelin: Hexarelin is a potent synthetic hexapeptide GHRP (Growth Hormone-Releasing Peptide) that stimulates GH release via the ghrelin receptor. It produces among the highest GH pulses of any GHRP, but also elevates cortisol and prolactin — a trade-off that distinguishes it from more selective options like Ipamorelin. MK-677 (Ibutamoren): Oral non-peptide growth hormone secretagogue that mimics ghrelin to stimulate GH and IGF-1 release without injection. Long half-life (~24 hours) enables once-daily oral dosing. Widely researched for body composition, sleep quality, and IGF-1 elevation. Both are in the Performance & Growth Hormone category but differ in mechanism, dosing, and research evidence — see the full comparison.

Can you take Hexarelin and MK-677 (Ibutamoren) together?

There is no specific, well-documented interaction rule for combining Hexarelin and MK-677 (Ibutamoren) in the aggregated research reviewed. Combining peptides should only be considered under professional supervision. This is not medical advice.

Which is better researched, Hexarelin or MK-677 (Ibutamoren)?

Hexarelin is currently preclinical only and MK-677 (Ibutamoren) is research-stage. "Better researched" depends on your research goal — review each profile's cited sources.

Performance & Growth Hormone · Comparison

Hexarelin vs MK-677 (Ibutamoren)

A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

Hexarelin

Preclinical only

Hexarelin is a potent synthetic hexapeptide GHRP (Growth Hormone-Releasing Peptide) that stimulates GH release via the ghrelin receptor. It produces among the highest GH pulses of any GHRP, but also elevates cortisol and prolactin — a trade-off that distinguishes it from more selective options like Ipamorelin.

Full profile

MK-677 (Ibutamoren)

Research-stage

Oral non-peptide growth hormone secretagogue that mimics ghrelin to stimulate GH and IGF-1 release without injection. Long half-life (~24 hours) enables once-daily oral dosing. Widely researched for body composition, sleep quality, and IGF-1 elevation.

Full profile

	Hexarelin	MK-677 (Ibutamoren)
Category	Performance & Growth Hormone	Performance & Growth Hormone
Also known as	Examorelin, EP 23905, MF-6003	Ibutamoren, Nutrobal, MK677, L-163,191
Evidence	Preclinical only	Research-stage
Dosing range	50mcg–200mcg mcg, 1–3x daily (cycling recommended to prevent desensitization)	10mg–50mg mg, once daily oral
Administration	Subcutaneous injection, Intramuscular injection	Oral (capsule/liquid)
Key side effects	Cortisol elevation, Prolactin elevation, Water retention, Increased appetite	Water retention, Increased appetite, Elevated fasting glucose (long-term), Fatigue (initial, transient)
Cited sources	1 reference	2 references

Key differences

Evidence level differs: Hexarelin is preclinical only, while MK-677 (Ibutamoren) is research-stage.
Administration: Hexarelin — Subcutaneous injection, Intramuscular injection; MK-677 (Ibutamoren) — Oral (capsule/liquid).
Dosing units differ: Hexarelin is dosed in mcg, MK-677 (Ibutamoren) in mg — they operate at different scales.
Frequency: Hexarelin is typically 1–3x daily (cycling recommended to prevent desensitization); MK-677 (Ibutamoren) is once daily oral.
Research depth: this profile cites 1 source for Hexarelin vs 2 for MK-677 (Ibutamoren).

How each works

Hexarelin

Hexarelin produces dose-dependent GH release significantly greater than GHRP-6 or Ipamorelin. It also has direct cardioprotective effects via CD36 receptor binding, independent of GH — making it unique among GHRPs. Studies show protection from ischemic cardiac injury and myocardial fibrosis reduction in animal models. Desensitization occurs with chronic continuous use.

MK-677 (Ibutamoren)

MK-677 binds the ghrelin receptor (GHS-R1a) to stimulate pulsatile GH release and increase circulating IGF-1. Unlike peptide GHRPs it survives oral administration. Clinical trials demonstrate significant increases in GH pulsatility and IGF-1 without suppression of the endogenous GH axis, though long-term use raises glucose metabolism concerns.

Read the full Hexarelin profile Read the full MK-677 (Ibutamoren) profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.